Relapsed Acute Myeloid Leukemia Drug Market
1 Study Coverage
1.1 Relapsed Acute Myeloid Leukemia Drug Product Introduction
1.2 Market by Type
1.2.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 aNK Program
1.2.3 AT-9283
1.2.4 BI-836858
1.2.5 Binimetinib
1.2.6 BL-8040
1.2.7 Others
1.3 Market by Application
1.3.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region
2.4.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2017-2022)
2.4.2 Global Sales Relapsed Acute Myeloid Leukemia Drug by Region (2023-2028)
2.5 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region
2.5.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2017-2022)
2.5.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Manufacturers
3.1.1 Global Top Relapsed Acute Myeloid Leukemia Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Relapsed Acute Myeloid Leukemia Drug in 2021
3.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers
3.2.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Relapsed Acute Myeloid Leukemia Drug Revenue in 2021
3.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Relapsed Acute Myeloid Leukemia Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Relapsed Acute Myeloid Leukemia Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Type
4.1.1 Global Relapsed Acute Myeloid Leukemia Drug Historical Sales by Type (2017-2022)
4.1.2 Global Relapsed Acute Myeloid Leukemia Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2028)
4.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type
4.2.1 Global Relapsed Acute Myeloid Leukemia Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Relapsed Acute Myeloid Leukemia Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2017-2028)
4.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Type
4.3.1 Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2017-2022)
4.3.2 Global Relapsed Acute Myeloid Leukemia Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Application
5.1.1 Global Relapsed Acute Myeloid Leukemia Drug Historical Sales by Application (2017-2022)
5.1.2 Global Relapsed Acute Myeloid Leukemia Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2028)
5.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application
5.2.1 Global Relapsed Acute Myeloid Leukemia Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Relapsed Acute Myeloid Leukemia Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2017-2028)
5.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Application
5.3.1 Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2017-2022)
5.3.2 Global Relapsed Acute Myeloid Leukemia Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Type
6.1.1 North America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2028)
6.1.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2028)
6.2 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Application
6.2.1 North America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2028)
6.2.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2028)
6.3 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Country
6.3.1 North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2028)
6.3.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Type
7.1.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2028)
7.1.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2028)
7.2 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Application
7.2.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2028)
7.2.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2028)
7.3 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Country
7.3.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2028)
7.3.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Size by Type
8.1.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Size by Application
8.2.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Size by Region
8.3.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Relapsed Acute Myeloid Leukemia Drug Market Size by Type
9.1.1 Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2028)
9.1.2 Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2028)
9.2 Latin America Relapsed Acute Myeloid Leukemia Drug Market Size by Application
9.2.1 Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2028)
9.2.2 Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2028)
9.3 Latin America Relapsed Acute Myeloid Leukemia Drug Market Size by Country
9.3.1 Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2028)
9.3.2 Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size by Type
10.1.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size by Application
10.2.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size by Country
10.3.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 4SC AG
11.1.1 4SC AG Corporation Information
11.1.2 4SC AG Overview
11.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 4SC AG Recent Developments
11.2 AbbVie Inc.
11.2.1 AbbVie Inc. Corporation Information
11.2.2 AbbVie Inc. Overview
11.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AbbVie Inc. Recent Developments
11.3 Actinium Pharmaceuticals, Inc.
11.3.1 Actinium Pharmaceuticals, Inc. Corporation Information
11.3.2 Actinium Pharmaceuticals, Inc. Overview
11.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Actinium Pharmaceuticals, Inc. Recent Developments
11.4 Agios Pharmaceuticals, Inc.
11.4.1 Agios Pharmaceuticals, Inc. Corporation Information
11.4.2 Agios Pharmaceuticals, Inc. Overview
11.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Agios Pharmaceuticals, Inc. Recent Developments
11.5 Amgen Inc.
11.5.1 Amgen Inc. Corporation Information
11.5.2 Amgen Inc. Overview
11.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Amgen Inc. Recent Developments
11.6 Arog Pharmaceuticals, Inc.
11.6.1 Arog Pharmaceuticals, Inc. Corporation Information
11.6.2 Arog Pharmaceuticals, Inc. Overview
11.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Arog Pharmaceuticals, Inc. Recent Developments
11.7 Array BioPharma Inc.
11.7.1 Array BioPharma Inc. Corporation Information
11.7.2 Array BioPharma Inc. Overview
11.7.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Array BioPharma Inc. Recent Developments
11.8 Astellas Pharma Inc.
11.8.1 Astellas Pharma Inc. Corporation Information
11.8.2 Astellas Pharma Inc. Overview
11.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Astellas Pharma Inc. Recent Developments
11.9 Astex Pharmaceuticals, Inc.
11.9.1 Astex Pharmaceuticals, Inc. Corporation Information
11.9.2 Astex Pharmaceuticals, Inc. Overview
11.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Astex Pharmaceuticals, Inc. Recent Developments
11.10 AstraZeneca Plc
11.10.1 AstraZeneca Plc Corporation Information
11.10.2 AstraZeneca Plc Overview
11.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 AstraZeneca Plc Recent Developments
11.11 AVEO Pharmaceuticals, Inc.
11.11.1 AVEO Pharmaceuticals, Inc. Corporation Information
11.11.2 AVEO Pharmaceuticals, Inc. Overview
11.11.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 AVEO Pharmaceuticals, Inc. Recent Developments
11.12 BioLineRx, Ltd.
11.12.1 BioLineRx, Ltd. Corporation Information
11.12.2 BioLineRx, Ltd. Overview
11.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 BioLineRx, Ltd. Recent Developments
11.13 Boehringer Ingelheim GmbH
11.13.1 Boehringer Ingelheim GmbH Corporation Information
11.13.2 Boehringer Ingelheim GmbH Overview
11.13.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Boehringer Ingelheim GmbH Recent Developments
11.14 Boston Biomedical, Inc.
11.14.1 Boston Biomedical, Inc. Corporation Information
11.14.2 Boston Biomedical, Inc. Overview
11.14.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Boston Biomedical, Inc. Recent Developments
11.15 Bristol-Myers Squibb Company
11.15.1 Bristol-Myers Squibb Company Corporation Information
11.15.2 Bristol-Myers Squibb Company Overview
11.15.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Bristol-Myers Squibb Company Recent Developments
11.16 Calithera Biosciences, Inc.
11.16.1 Calithera Biosciences, Inc. Corporation Information
11.16.2 Calithera Biosciences, Inc. Overview
11.16.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Calithera Biosciences, Inc. Recent Developments
11.17 Celgene Corporation
11.17.1 Celgene Corporation Corporation Information
11.17.2 Celgene Corporation Overview
11.17.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Celgene Corporation Recent Developments
11.18 Cornerstone Pharmaceuticals, Inc.
11.18.1 Cornerstone Pharmaceuticals, Inc. Corporation Information
11.18.2 Cornerstone Pharmaceuticals, Inc. Overview
11.18.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Cornerstone Pharmaceuticals, Inc. Recent Developments
11.19 CTI BioPharma Corp.
11.19.1 CTI BioPharma Corp. Corporation Information
11.19.2 CTI BioPharma Corp. Overview
11.19.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 CTI BioPharma Corp. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Relapsed Acute Myeloid Leukemia Drug Industry Chain Analysis
12.2 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Relapsed Acute Myeloid Leukemia Drug Production Mode & Process
12.4 Relapsed Acute Myeloid Leukemia Drug Sales and Marketing
12.4.1 Relapsed Acute Myeloid Leukemia Drug Sales Channels
12.4.2 Relapsed Acute Myeloid Leukemia Drug Distributors
12.5 Relapsed Acute Myeloid Leukemia Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Relapsed Acute Myeloid Leukemia Drug Industry Trends
13.2 Relapsed Acute Myeloid Leukemia Drug Market Drivers
13.3 Relapsed Acute Myeloid Leukemia Drug Market Challenges
13.4 Relapsed Acute Myeloid Leukemia Drug Market Restraints
14 Key Findings in The Global Relapsed Acute Myeloid Leukemia Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of aNK Program
Table 3. Major Manufacturers of AT-9283
Table 4. Major Manufacturers of BI-836858
Table 5. Major Manufacturers of Binimetinib
Table 6. Major Manufacturers of BL-8040
Table 7. Major Manufacturers of Others
Table 8. Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 9. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 10. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2017-2022) & (K Pcs)
Table 11. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2017-2022)
Table 12. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2023-2028) & (K Pcs)
Table 13. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2023-2028)
Table 14. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2017-2022) & (US$ Million)
Table 15. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2017-2022)
Table 16. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2023-2028) & (US$ Million)
Table 17. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2023-2028)
Table 18. Global Relapsed Acute Myeloid Leukemia Drug Sales by Manufacturers (2017-2022) & (K Pcs)
Table 19. Global Relapsed Acute Myeloid Leukemia Drug Sales Share by Manufacturers (2017-2022)
Table 20. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 21. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers (2017-2022)
Table 22. Relapsed Acute Myeloid Leukemia Drug Price by Manufacturers (2017-2022) &(USD/Pcs)
Table 23. Global Relapsed Acute Myeloid Leukemia Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Relapsed Acute Myeloid Leukemia Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Relapsed Acute Myeloid Leukemia Drug as of 2021)
Table 25. Relapsed Acute Myeloid Leukemia Drug Manufacturing Base Distribution and Headquarters
Table 26. Manufacturers Relapsed Acute Myeloid Leukemia Drug Product Offered
Table 27. Date of Manufacturers Enter into Relapsed Acute Myeloid Leukemia Drug Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2022) & (K Pcs)
Table 30. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2023-2028) & (K Pcs)
Table 31. Global Relapsed Acute Myeloid Leukemia Drug Sales Share by Type (2017-2022)
Table 32. Global Relapsed Acute Myeloid Leukemia Drug Sales Share by Type (2023-2028)
Table 33. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2022) & (US$ Million)
Table 34. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2023-2028) & (US$ Million)
Table 35. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Type (2017-2022)
Table 36. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Type (2023-2028)
Table 37. Relapsed Acute Myeloid Leukemia Drug Price by Type (2017-2022) & (USD/Pcs)
Table 38. Global Relapsed Acute Myeloid Leukemia Drug Price Forecast by Type (2023-2028) & (USD/Pcs)
Table 39. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2022) & (K Pcs)
Table 40. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2023-2028) & (K Pcs)
Table 41. Global Relapsed Acute Myeloid Leukemia Drug Sales Share by Application (2017-2022)
Table 42. Global Relapsed Acute Myeloid Leukemia Drug Sales Share by Application (2023-2028)
Table 43. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2022) & (US$ Million)
Table 44. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2023-2028) & (US$ Million)
Table 45. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Application (2017-2022)
Table 46. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Application (2023-2028)
Table 47. Relapsed Acute Myeloid Leukemia Drug Price by Application (2017-2022) & (USD/Pcs)
Table 48. Global Relapsed Acute Myeloid Leukemia Drug Price Forecast by Application (2023-2028) & (USD/Pcs)
Table 49. North America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2022) & (K Pcs)
Table 50. North America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2023-2028) & (K Pcs)
Table 51. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2022) & (US$ Million)
Table 52. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2023-2028) & (US$ Million)
Table 53. North America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2022) & (K Pcs)
Table 54. North America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2023-2028) & (K Pcs)
Table 55. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2022) & (US$ Million)
Table 56. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2023-2028) & (US$ Million)
Table 57. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2022) & (K Pcs)
Table 58. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2023-2028) & (K Pcs)
Table 59. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2022) & (US$ Million)
Table 60. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2023-2028) & (US$ Million)
Table 61. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2022) & (K Pcs)
Table 62. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Type (2023-2028) & (K Pcs)
Table 63. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2022) & (US$ Million)
Table 64. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2023-2028) & (US$ Million)
Table 65. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2022) & (K Pcs)
Table 66. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Application (2023-2028) & (K Pcs)
Table 67. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2022) & (US$ Million)
Table 68. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2023-2028) & (US$ Million)
Table 69. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2022) & (K Pcs)
Table 70. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2023-2028) & (K Pcs)
Table 71. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2022) & (US$ Million)
Table 72. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2023-2028) & (US$ Million)
Table 73. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2022) & (K Pcs)
Table 74. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Type (2023-2028) & (K Pcs)
Table 75. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2022) & (US$ Million)
Table 76. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2023-2028) & (US$ Million)
Table 77. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2022) & (K Pcs)
Table 78. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Application (2023-2028) & (K Pcs)
Table 79. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2022) & (US$ Million)
Table 80. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2023-2028) & (US$ Million)
Table 81. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Region (2017-2022) & (K Pcs)
Table 82. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Region (2023-2028) & (K Pcs)
Table 83. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2017-2022) & (US$ Million)
Table 84. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2023-2028) & (US$ Million)
Table 85. Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2022) & (K Pcs)
Table 86. Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2023-2028) & (K Pcs)
Table 87. Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2022) & (US$ Million)
Table 88. Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2023-2028) & (US$ Million)
Table 89. Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2022) & (K Pcs)
Table 90. Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2023-2028) & (K Pcs)
Table 91. Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2022) & (US$ Million)
Table 92. Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2023-2028) & (US$ Million)
Table 93. Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2022) & (K Pcs)
Table 94. Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2023-2028) & (K Pcs)
Table 95. Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2022) & (US$ Million)
Table 96. Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2022) & (K Pcs)
Table 98. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Type (2023-2028) & (K Pcs)
Table 99. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2022) & (K Pcs)
Table 102. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Application (2023-2028) & (K Pcs)
Table 103. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2023-2028) & (US$ Million)
Table 105. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2022) & (K Pcs)
Table 106. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2023-2028) & (K Pcs)
Table 107. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2022) & (US$ Million)
Table 108. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2023-2028) & (US$ Million)
Table 109. 4SC AG Corporation Information
Table 110. 4SC AG Description and Major Businesses
Table 111. 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 112. 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. 4SC AG Recent Developments
Table 114. AbbVie Inc. Corporation Information
Table 115. AbbVie Inc. Description and Major Businesses
Table 116. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 117. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. AbbVie Inc. Recent Developments
Table 119. Actinium Pharmaceuticals, Inc. Corporation Information
Table 120. Actinium Pharmaceuticals, Inc. Description and Major Businesses
Table 121. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 122. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. Actinium Pharmaceuticals, Inc. Recent Developments
Table 124. Agios Pharmaceuticals, Inc. Corporation Information
Table 125. Agios Pharmaceuticals, Inc. Description and Major Businesses
Table 126. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 127. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Agios Pharmaceuticals, Inc. Recent Developments
Table 129. Amgen Inc. Corporation Information
Table 130. Amgen Inc. Description and Major Businesses
Table 131. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 132. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. Amgen Inc. Recent Developments
Table 134. Arog Pharmaceuticals, Inc. Corporation Information
Table 135. Arog Pharmaceuticals, Inc. Description and Major Businesses
Table 136. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 137. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 138. Arog Pharmaceuticals, Inc. Recent Developments
Table 139. Array BioPharma Inc. Corporation Information
Table 140. Array BioPharma Inc. Description and Major Businesses
Table 141. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 142. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 143. Array BioPharma Inc. Recent Developments
Table 144. Astellas Pharma Inc. Corporation Information
Table 145. Astellas Pharma Inc. Description and Major Businesses
Table 146. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 147. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 148. Astellas Pharma Inc. Recent Developments
Table 149. Astex Pharmaceuticals, Inc. Corporation Information
Table 150. Astex Pharmaceuticals, Inc. Description and Major Businesses
Table 151. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 152. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 153. Astex Pharmaceuticals, Inc. Recent Developments
Table 154. AstraZeneca Plc Corporation Information
Table 155. AstraZeneca Plc Description and Major Businesses
Table 156. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 157. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 158. AstraZeneca Plc Recent Developments
Table 159. AVEO Pharmaceuticals, Inc. Corporation Information
Table 160. AVEO Pharmaceuticals, Inc. Description and Major Businesses
Table 161. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 162. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 163. AVEO Pharmaceuticals, Inc. Recent Developments
Table 164. BioLineRx, Ltd. Corporation Information
Table 165. BioLineRx, Ltd. Description and Major Businesses
Table 166. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 167. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 168. BioLineRx, Ltd. Recent Developments
Table 169. Boehringer Ingelheim GmbH Corporation Information
Table 170. Boehringer Ingelheim GmbH Description and Major Businesses
Table 171. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 172. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 173. Boehringer Ingelheim GmbH Recent Developments
Table 174. Boston Biomedical, Inc. Corporation Information
Table 175. Boston Biomedical, Inc. Description and Major Businesses
Table 176. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 177. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 178. Boston Biomedical, Inc. Recent Developments
Table 179. Bristol-Myers Squibb Company Corporation Information
Table 180. Bristol-Myers Squibb Company Description and Major Businesses
Table 181. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 182. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 183. Bristol-Myers Squibb Company Recent Developments
Table 184. Calithera Biosciences, Inc. Corporation Information
Table 185. Calithera Biosciences, Inc. Description and Major Businesses
Table 186. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 187. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 188. Calithera Biosciences, Inc. Recent Developments
Table 189. Celgene Corporation Corporation Information
Table 190. Celgene Corporation Description and Major Businesses
Table 191. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 192. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 193. Celgene Corporation Recent Developments
Table 194. Cornerstone Pharmaceuticals, Inc. Corporation Information
Table 195. Cornerstone Pharmaceuticals, Inc. Description and Major Businesses
Table 196. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 197. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 198. Cornerstone Pharmaceuticals, Inc. Recent Developments
Table 199. CTI BioPharma Corp. Corporation Information
Table 200. CTI BioPharma Corp. Description and Major Businesses
Table 201. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 202. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 203. CTI BioPharma Corp. Recent Developments
Table 204. Key Raw Materials Lists
Table 205. Raw Materials Key Suppliers Lists
Table 206. Relapsed Acute Myeloid Leukemia Drug Distributors List
Table 207. Relapsed Acute Myeloid Leukemia Drug Customers List
Table 208. Relapsed Acute Myeloid Leukemia Drug Market Trends
Table 209. Relapsed Acute Myeloid Leukemia Drug Market Drivers
Table 210. Relapsed Acute Myeloid Leukemia Drug Market Challenges
Table 211. Relapsed Acute Myeloid Leukemia Drug Market Restraints
Table 212. Research Programs/Design for This Report
Table 213. Key Data Information from Secondary Sources
Table 214. Key Data Information from Primary Sources
List of Figures
Figure 1. Relapsed Acute Myeloid Leukemia Drug Product Picture
Figure 3. Global Relapsed Acute Myeloid Leukemia Drug Market Share by Type in 2021 & 2028
Figure 3. aNK Program Product Picture
Figure 4. AT-9283 Product Picture
Figure 5. BI-836858 Product Picture
Figure 6. Binimetinib Product Picture
Figure 7. BL-8040 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Relapsed Acute Myeloid Leukemia Drug Market Share by Application in 2021 & 2028
Figure 10. Clinic
Figure 11. Hospital
Figure 12. Others
Figure 13. Relapsed Acute Myeloid Leukemia Drug Report Years Considered
Figure 14. Global Relapsed Acute Myeloid Leukemia Drug Sales 2017-2028 (K Pcs)
Figure 15. Global Relapsed Acute Myeloid Leukemia Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 16. Global Relapsed Acute Myeloid Leukemia Drug Revenue 2017-2028 (US$ Million)
Figure 17. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 18. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2017-2022)
Figure 19. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2023-2028)
Figure 20. North America Relapsed Acute Myeloid Leukemia Drug Sales YoY (2017-2028) & (K Pcs)
Figure 21. North America Relapsed Acute Myeloid Leukemia Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Europe Relapsed Acute Myeloid Leukemia Drug Sales YoY (2017-2028) & (K Pcs)
Figure 23. Europe Relapsed Acute Myeloid Leukemia Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales YoY (2017-2028) & (K Pcs)
Figure 25. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Latin America Relapsed Acute Myeloid Leukemia Drug Sales YoY (2017-2028) & (K Pcs)
Figure 27. Latin America Relapsed Acute Myeloid Leukemia Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 28. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales YoY (2017-2028) & (K Pcs)
Figure 29. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 30. The Relapsed Acute Myeloid Leukemia Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 31. The Top 5 and 10 Largest Manufacturers of Relapsed Acute Myeloid Leukemia Drug in the World: Market Share by Relapsed Acute Myeloid Leukemia Drug Revenue in 2021
Figure 32. Global Relapsed Acute Myeloid Leukemia Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 33. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2028)
Figure 34. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2017-2028)
Figure 35. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2028)
Figure 36. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2017-2028)
Figure 37. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2028)
Figure 38. North America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2017-2028)
Figure 39. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2028)
Figure 40. North America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2017-2028)
Figure 41. North America Relapsed Acute Myeloid Leukemia Drug Sales Share by Country (2017-2028)
Figure 42. North America Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country (2017-2028)
Figure 43. U.S. Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 44. Canada Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 45. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2028)
Figure 46. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2017-2028)
Figure 47. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2028)
Figure 48. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2017-2028)
Figure 49. Europe Relapsed Acute Myeloid Leukemia Drug Sales Share by Country (2017-2028)
Figure 50. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country (2017-2028)
Figure 51. Germany Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 52. France Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 53. U.K. Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 54. Italy Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 55. Russia Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 56. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2028)
Figure 57. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2017-2028)
Figure 58. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2028)
Figure 59. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2017-2028)
Figure 60. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales Share by Region (2017-2028)
Figure 61. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Share by Region (2017-2028)
Figure 62. China Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 63. Japan Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 64. South Korea Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 65. India Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 66. Australia Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 67. Taiwan Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 68. Indonesia Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 69. Thailand Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 70. Malaysia Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 71. Philippines Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 72. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2028)
Figure 73. Latin America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2017-2028)
Figure 74. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2028)
Figure 75. Latin America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2017-2028)
Figure 76. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Share by Country (2017-2028)
Figure 77. Latin America Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country (2017-2028)
Figure 78. Mexico Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 79. Brazil Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 80. Argentina Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 81. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2028)
Figure 82. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2017-2028)
Figure 83. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2028)
Figure 84. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2017-2028)
Figure 85. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Share by Country (2017-2028)
Figure 86. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country (2017-2028)
Figure 87. Turkey Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 88. Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 89. UAE Relapsed Acute Myeloid Leukemia Drug Revenue (2017-2028) & (US$ Million)
Figure 90. Relapsed Acute Myeloid Leukemia Drug Value Chain
Figure 91. Relapsed Acute Myeloid Leukemia Drug Production Process
Figure 92. Channels of Distribution
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed
Industry Market Size
